Floatz logo

AVOLVE

Benign Prostatic Hyperplasia

Turku University HospitalSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Benign Prostatic Hyperplasia cohort.

Asset / SponsorPhaseRating
DINITROGEN MONOXIDE
Beth Israel Deaconess Medical Center
Phase 4BB
TESTOSTERONE UNDECYLATE
University of Florence
Phase 4BB
Oxygen
Beth Israel Deaconess Medical Center
Phase 4BB
DICLOFENAC
Taha Uçar
Phase 4BB
Jalyn
Dr. J. Curtis Nickel
Phase 3B

View all 17 →

Same molecule, other indications

AVOLVE is also rated in:

prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
Lower Urinary Tract SymptomsDormant
B
Indicative ·
57 / 100
View asset →
erectile dysfunctionDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →